SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced that its Immunoscore Colon Cancer test has been included in the Pan-Asian adapted ESMO 1 Clinical Practice ...
In the absence of convincing direct evidence, the identification of high-risk stage II subgroups permits a justification for adjuvant chemotherapy in node-negative disease. Current stratification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results